title: [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].
abstract: This study was performed to evaluate the risk of gallstone formation during long-term treatment with the long-acting somatostatin analog octreotide (SMS 201-995). Twelve patients (8 men, 4 women--mean age 43 years) treated with continuous subcutaneous octreotide infusion for acromegaly (mean duration 26.5 months, mean dose 541 micrograms/day) were included. Bile collection by duodenal intubation was performed before, during, and 45 days after octreotide treatment in 3, 12, and 8 patients, respectively. Abdominal ultrasonography and/or oral cholecystrography were also performed before (n = 9 patients), during (n = 12), and after treatment (n = 10). Bile examination was normal in the 3 patients controlled before treatment but showed that 58.3 percent of the treated patients had cholesterol monohydrate crystals. After discontinuation of octreotide only 25 percent of patients had cholesterol crystals. In 3 patients (25 percent) treated longer than 6 months, cholesterol crystals occurred prior to the occurrence of small radiolucent gallstones: one patient underwent cholecystectomy because of biliary colic, while in the two others, complete dissolution of stones was obtained after 10 months of treatment with ursodeoxycholic acid given in association with octreotide. None of the 9 other acromegalic patients (including 7 treated more than 20 months) developed stones. Cholesterol gallstone formation seems to be increased in acromegalic patients during long-term octreotide treatment but the exact incidence remains to be determined in larger series of patients.
authors.affiliation: Clinique des Maladies de l'Appareil Digestif et INSERM U151, CHU Rangueil, Toulouse.
authors.forename: L E
authors.initials: LE
authors.lastname: Buscail
authors.forename: C
authors.initials: C
authors.lastname: Puel-Bousquet
authors.forename: A G
authors.initials: AG
authors.lastname: Harris
authors.forename: J P
authors.initials: JP
authors.lastname: Tauber
authors.forename: J R
authors.initials: JR
authors.lastname: Escourrou
authors.forename: M M
authors.initials: MM
authors.lastname: Delvaux
authors.forename: N M
authors.initials: NM
authors.lastname: Vaysse
authors.forename: F
authors.initials: F
authors.lastname: Bayard
authors.forename: A
authors.initials: A
authors.lastname: Ribet
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001649:Bile Duct Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy; D002769:Cholelithiasis / Q000139:chemically induced* / Q000737:chemistry / Q000000981:diagnostic imaging / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D014463:Ultrasonography; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D014580:Ursodeoxycholic Acid; D015282:Octreotide
vernacular_title: Effets sur la lithogenèse biliaire du traitement au long cours par octréotide (SMS 201-995) chez des patients acromégales.